Who are Postop acetaminophen IV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, néfopam, Per Os Acetaminophen, Nefopam administration and prelevment, Nefopam ampule, hydrocodone / acetaminophen extended release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/postop-acetaminophen-iv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Postop acetaminophen IV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postop acetaminophen IV (Postop acetaminophen IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic; antipyretic. Area: Pain Management.

marketed Non-opioid analgesic; antipyretic Cyclooxygenase (COX) enzymes Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Postop acetaminophen IV (Postop acetaminophen IV) — AdventHealth. Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Postop acetaminophen IV TARGET	Postop acetaminophen IV	AdventHealth	marketed	Non-opioid analgesic; antipyretic	Cyclooxygenase (COX) enzymes
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
néfopam	néfopam	University Hospital, Bordeaux	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT)
Per Os Acetaminophen	Per Os Acetaminophen	Hospital for Special Surgery, New York	marketed	Non-opioid analgesic and antipyretic	Cyclooxygenase (COX), primarily in central nervous system
Nefopam administration and prelevment	Nefopam administration and prelevment	University Hospital, Rouen	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter
Nefopam ampule	Nefopam ampule	Ministry Of Health / Nineveh Health Directorate	phase 3	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter
hydrocodone / acetaminophen extended release	hydrocodone / acetaminophen extended release	Abbott	phase 3	Opioid agonist / non-opioid analgesic	Opioid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-opioid analgesic; antipyretic class)

AdventHealth · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Postop acetaminophen IV — Competitive Intelligence Brief. https://druglandscape.com/ci/postop-acetaminophen-iv. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing